Molecular Mechanisms of Renal Blood Flow Autoregulation

Marilyn Burke, Mallikarjuna R. Pabbidi, Jerry Farley and Richard J. Roman*

Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA

Abstract: Diabetes and hypertension are the leading causes of chronic kidney disease and their incidence is increasing at an alarming rate. Both are associated with impairments in the autoregulation of renal blood flow (RBF) and greater transmission of fluctuations in arterial pressure to the glomerular capillaries. The ability of the kidney to maintain relatively constant blood flow, glomerular filtration rate (GFR) and glomerular capillary pressure is mediated by the myogenic response of afferent arterioles working in concert with tubuloglomerular feedback that adjusts the tone of the afferent arteriole in response to changes in the delivery of sodium chloride to the macula densa. Despite intensive investigation, the factors initiating the myogenic response and the signaling pathways involved in the myogenic response and tubuloglomerular feedback remain uncertain. This review focuses on current thought regarding the molecular mechanisms underlying myogenic control of renal vascular tone, the interrelationships between the myogenic response and tubuloglomerular feedback, the evidence that alterations in autoregulation of RBF contributes to hypertension and diabetes-induced nephropathy and the identification of vascular therapeutic targets for improved renoprotection in hypertensive and diabetic patients.

Keywords: Afferent arteriole, glomerulus, kidney, myogenic response, tubuloglomerular feedback.

INTRODUCTION

Renal blood flow (RBF) autoregulation is a vital homeostatic mechanism that protects the kidney from elevations in arterial pressure that would be transmitted to the glomerular capillaries and cause injury. It also allows the kidney to maintain a relatively constant blood flow and glomerular filtration rate (GFR) necessary for the clearance of metabolic wastes while maintaining efficient recovery of filtered electrolytes and nutrients by the renal tubules. Two mechanisms contribute to autoregulation of RBF. The first is the myogenic response of preglomerular arterioles. Elevations in transmural pressure induce contraction of preglomerular arterioles, predominantly at the level of afferent arterioles. The other mechanism is tubuloglomerular feedback which acts in concert with the myogenic response. It senses changes in the concentration of sodium chloride in the tubular fluid reaching the macula densa cells in the distal tubule and adjusts the diameter of the afferent arteriole accordingly [1, 2]. Tubuloglomerular feedback serves as an effective autoregulatory mechanism because the sodium chloride concentration of the fluid reaching the macula densa is dependent on flow rate, which in turn, is related to the GFR and glomerular capillary pressure.

As is presented in (Fig. 1), RBF remains relatively constant in normal rats over a range of mean arterial pressures between 90 and 150 mmHg and from 70 to 130 mmHg in humans. The myogenic response of the afferent arterioles accounts for most of the rapid compensation to changes in arterial pressure in the range of 0.1 to 0.3Hz (3-10 secs). Tubuloglomerular feedback acts more slowly, and contributes more to the compensation to slow changes in arterial pressure in the range of 0.05Hz (>20 seconds) [3-8]. In general, the available evidence indicates that the myogenic response is most important in protecting the glomerular capillaries against rapid elevations in arterial pressure, while tubuloglomerular feedback is more involved in maintaining RBF and GFR in response to sustained reductions in arterial pressure [9-13].

Elevations in vascular resistance, especially in the renal circulation, are characteristic of hypertension. There is also generalized endothelial dysfunction associated with diminished vasodilatory responses to shear stress and other stimuli. In the spontaneously hypertensive rat (SHR) and angiotensin II dependent models of hypertension and in patients with mild or moderate hypertension, there is an elevation in renal vascular resistance that is in general appropriate for the degree of hypertension, so baseline RBF and GFR remain in the normal range and renal damage is minimal [14, 15]. However, the range of autoregulation of RBF is shifted to higher pressures and the magnitude of the shift is dependent on the severity and duration of the hypertension [16, 17] (Fig. 1), which is largely due to hypertrophy and thickening of the wall of the preglomerular arterioles [18], and potentiation of myogenic responsiveness [19-22]. In patients with moderate hypertension, the shift in the autoregulatory relationship is not severe and arterial pressure can still be lowered into the normotensive range with antihypertensive therapy without compromising renal function. In more malignant forms of hypertension, however, the hypertrophy of the vascular wall narrows the lumen of preglomerular arterioles sufficiently to lower baseline RBF and GFR and it is often not possible to lower blood pressure into the normotensive range without a decline in renal function [23]. Under these conditions, a gradual reduction in blood pressure is recommended.
In contrast to the increase in renal vascular resistance and augmented myogenic autoregulatory responses observed in SHR and in patients with essential hypertension, autoregulation of RBF is impaired in Fawn Hooded Hypertensive (FHH) rats [24, 25], Dahl salt-sensitive rats [26-28], rats with mineralocorticoid induced hypertension [29, 30] and in animals with reduced renal mass [31] (Fig. 1). The impairment of RBF autoregulation leads to increased glomerular capillary pressure and glomerular injury with the development of proteinuria, glomerulosclerosis and renal fibrosis in Dahl salt sensitive [32], FHH [25, 33-35] and in hypertensive rats treated with deoxycorticosterone acetate (DOCA) and a high salt diet. A similar abnormality in glomerular capillary hemodynamics is thought to contribute to the rapid development of glomerulosclerosis in hypertensive African American patients [36] who are four times more likely to develop chronic kidney disease than caucasian patients [37-41]. Alterations in renal hemodynamics is also thought to play a critical role in the initiation and progression of diabetic nephropathy [42]. Hypertension and diabetes now account for 67% of new cases of end-stage renal disease with total estimated cost in 2007 of $35.3 billion ($23.9 billion in Medicare costs alone) for the treatment of an estimated 500,000 patients in the US [43]. Thus, new therapies for slowing the development and progression of glomerulosclerosis in diabetic and hypertensive patients is of utmost importance. A better understanding of the molecular mechanisms underlying renal autoregulation is key to someday achieving this goal.

**MYOGENIC RESPONSE**

The myogenic response is an intrinsic property of vascular smooth muscle (VSM) that allows arterioles to constrict in response to elevations in transmural pressure. The myogenic response can be readily demonstrated in de-endothelialized arterioles in vitro devoid of endothelial or parenchymal influences [44-46]. Despite intensive investigation, identification of the mechanosensors responsible for initiating the myogenic response and many aspects of the signaling pathways remain uncertain. The myogenic response involves stretch activation of mechanosensitive ion channels resulting in depolarization of VSM cells and calcium influx through L-type voltage-gated calcium channels (VGCC), Ca$^{2+}$/calmodulin-dependent phosphorylation of myosin light chain kinase and sensitization of actinomyosin-based contractile mechanisms [47, 48]. There is evidence that the initial mechanotransduction event involves an interaction of cell surface integrins with extracellular matrix proteins such as fibronectin and actin filaments in the cytoskeleton, since blockade of integrins with integrin binding peptide inhibits Ca$^{2+}$ currents and myogenic tone of skeletal muscle arterioles [47-49]. There is also evidence that β and γ subunits of epithelial sodium channels (ENaC) are expressed in vascular smooth muscle cells and that they play some role in the mechanotransduction event since administration of blockers of ENaC; benzamil and amiloride, impair the myogenic response of isolated vessels [50-53]. Several investigators have identified non-selective cation channels in vascular smooth muscle cells that are activated by membrane stretch [54-56]. These channels were initially thought to be directly activated by membrane stretch to promote Na$^+$ or Ca$^{2+}$ entry which depolarizes VSM cells and facilitates Ca$^{2+}$ entry through VGCC to initiate the myogenic response. However, more recent evidence indicates that the stretch-activated cation channels are likely transient receptor potential melastatin 4 (TRPM4) and transient receptor potential canonical 6 (TRPC6) channels that respond to stretch through activation of second messenger signaling pathways rather than direct mechanical activation [57-59]. In support of this view, Early and Brayden have shown that both TRPM4 and TRPC6 channels are expressed in VSM cells and knockdown of the...
expression of these channels impairs the myogenic response in cerebral arteries \[58, 59\]. Similar studies in renal afferent arterioles have yet to be performed.

More recent data have indicated that the stretch activation of the TRP channels in cell systems requires co-expression of the channels with Gq dependent receptors, such as the angiotensin type 1, endothelin, vasopressin or histamine receptors \[57\]. An emerging view summarized in (Fig. 2) is that membrane stretch causes this class of receptors to interact with Gq proteins in the membrane to activate phospholipase C (PLC) and increase the production of diacylglycerol (DAG) and inositol trisphosphate (IP3) \[60\]. IP3 promotes the release of Ca\(^{2+}\) from the sarcoplasmic reticulum near the membrane such that local Ca\(^{2+}\) concentration can reach levels sufficient to activate TRPM4 channels to allow Na\(^{+}\) entry and depolarize the membrane \[58\]. DAG can also directly activate TRPC6 channels \[57\] and protein kinase C (PKC) which phosphorylates and sensitizes TRPM4 channels to increases in intracellular Ca\(^{2+}\) and enhances the degree of depolarization sufficiently to allow Ca\(^{2+}\) entry through VGCC. The activation of PKC also has additional actions to enhance the depolarization and activation of vascular smooth muscle. In this regard, PKC is known to phosphorylate the VGCC to enhance the voltage sensitivity of this channel to facilitate Ca\(^{2+}\) entry \[61\]. Indeed, there are studies indicating that inhibitors of PLC \[62\] and PKC \[63, 64\] block the myogenic response of renal and cerebral arteries.

Activation of non-selective cation channels (NSCC) such as TRPM4 or TRPC6 and subsequent local increases in intracellular Ca\(^{2+}\) also activate large conductance potassium channels, (BK) \[65-67\] (Fig. 2). BK channels are also activated by the transient calcium release (Ca\(^{2+}\) sparks) through ryanodine receptors located in the sarcoplasmic reticulum and in close proximity to these channels. In VSM cells, Ca\(^{2+}\) sparks give rise to spontaneous transient outward K\(^{+}\) currents (STOCs) that hyperpolarize the cells \[68\]. The magnitude and frequency of STOCs can be increased by membrane depolarization, sarcoplasmic reticulum Ca\(^{2+}\) release, and Ca\(^{2+}\) influx through VGCC \[69\]. The interplay between the activation of NSCC, Ca\(^{2+}\) sparks and activation of BK channels oppose depolarization of VSM cells and inhibit myogenic

![Fig. (2). Mechanisms involved in myogenic response of preglomerular renal arterioles.](image-url)
responsiveness [65, 66]. Thus, there must be mechanisms in place to blunt the opening of BK channels. In this regard, there is evidence that PKC phosphorylates and inhibits activation of BK channels [65, 66]. There is also considerable evidence that a cytochrome P450 metabolite of arachidonic acid, namely 20-hydroxyeicosatetraenoic acid (20-HETE), plays a key role in augmenting the myogenic response by blocking BK channels [63, 64, 70, 71]. In this regard, the rise in intracellular Ca\(^{2+}\) following stretch of VSM cells activates phospholipase A2 which stimulates the release of arachidonic acid (AA). AA has been shown to be avidly converted to 20-HETE by cytochrome P450 enzymes of the 4A family expressed in renal afferent arterioles [72]. 20-HETE is a potent constrictor of renal arterioles [73, 74] that activates PKC [63, 64, 75], mitogen activated protein kinase [76, 77], src-type tyrosine kinase [78] and rho kinase [79]. 20-HETE potentiates the myogenic response by activating PKC which has been shown to phosphorylate and inhibit BK channels thereby allowing for sustained depolarization of VSM cells [64, 70, 71, 80]. 20-HETE also augments activation of TRPC6 channels enhancing depolarization and increasing activity of L-type calcium channels [81]. Indeed, elevations of transmural pressure increase 20-HETE levels in isolated arterioles [82] and inhibitors of the synthesis of 20-HETE block the myogenic response in isolated renal [83] and cerebral arteries [82] in vitro and impair autoregulation of renal [84] and cerebral blood flow [82] in vivo.

The initial rise in intracellular calcium concentration following activation of the myogenic response is transient, generally falling to levels near or slightly elevated from baseline, whereas the vasoconstrictor response is sustained. This indicates that there must be an increase in the Ca\(^{2+}\) sensitivity of contractile apparatus that plays a key role in the response. As seen in (Fig. 2), the rise in intracellular Ca\(^{2+}\) is thought to activate myosin light chain kinase via a Ca\(^{2+}\)-calmodulin dependent process and phosphorylate the 20 kD regulatory subunit of myosin light chain. This permits the myosin light chain to more effectively bind to actin and hydrolyze ATP to enhance cross bridge formation and cycling. Myosin light chain phosphatase normally dephosphorylates the light chain to limit cross bridge formation and allow for diminished tone [85]. Recent studies indicate that the sustained activation of vascular smooth muscle cells is related not only to increased myosin light chain kinase activity but also to inhibition of myosin light chain phosphatase activity. This is due to the increase in PKC activity induced by DAG, [86, 87] and 20-HETE that activate a rho-A sensitive kinase that phosphorylates and inhibits the activity of myosin light chain phosphatase [79]. In summary, the myogenic response involves stretch activation of ion channels, depolarization and Ca\(^{2+}\) influx through VGCC that initiates contraction that is followed by other mechanisms that enhance the Ca\(^{2+}\) sensitivity of the contractile mechanism that are essential for the sustained contractile response.

TUBULOGLOMERULAR FEEDBACK

The other mechanism contributing to autoregulation of RBF is tubuloglomerular feedback [1, 2, 88]. This mechanism senses increases in the concentration of sodium chloride (NaCl) in tubular fluid reaching the macula densa cells of the distal nephron which then acts to decrease the diame-

ter of the juxtaposed afferent arteriole. Tubuloglomerular feedback serves as a negative feedback loop to stabilize GFR to enable excretion of metabolic waste and to prevent transmission of elevations in arterial pressure from being transmitted to the glomerular capillaries and damaging the glomerulus. A summary of the proposed mechanism of tubuloglomerular feedback is presented in (Fig. 3). Increases in arterial pressure, that are not fully compensated via the myogenic response, increase glomerular capillary pressure and GFR and inhibit Na\(^{+}\) reabsorption in the proximal tubule via the mechanism of pressure natriuresis [89, 90]. This leads to an increase in the concentration of NaCl delivered to the distal nephron which increases Na\(^{+}\) uptake by the Na-K-2Cl co-transporter in the apical membrane of the macula densa. The essential role of Na\(^{+}\) transport via the Na-K-2Cl cotransporter in triggering tubuloglomerular feedback is based on the observations that inclusion of loop diuretics in the tubular perfusate nearly completely blocks the tubuloglomerular feedback response [91–93] and the observation that targeted knockout of the Na-K-2Cl, A or B genes, impairs the tubuloglomerular feedback response in mice [94, 95]. The uptake of Na\(^{+}\) via the Na-K-2Cl transporter is thought to increase intracellular Na\(^{+}\) concentration and the activity of Na-K-ATPase and increase intracellular Ca\(^{2+}\) levels in the macula densa [96]. This is associated with increased release of ATP from the basolateral membrane of macula densa cells through a maxi anion channel [97, 98].

There still remains some controversy regarding whether the ATP that is released from the macula densa then acts directly on the afferent arteriole to elicit vasoconstriction through stimulation of the ATP P2X receptors or whether it is degraded by ecto-ATPases and nucleotidases to adenosine that constricts the afferent arteriole through activation of the adenosine A\(_{1A}\) receptor [99–104]. The evidence supporting the role for ATP in mediating tubuloglomerular feedback is that administration of the P2X\(_{1}\) receptor antagonist, NF-279, impairs the response of afferent arterioles to elevations in perfusion pressure in the isolated perfused juxtedudillary nephron preparation [105]. Similarly, knockout of the P2X\(_{1}\) receptor in mice impairs the response of afferent arterioles to elevations in perfusion pressure in the isolated perfused juxtedudillary nephron preparation [105, 106] and autoregulation of RBF in vivo [107] but tubuloglomerular feedback responses to increases in tubular flow to the macula densa in vivo are not significantly altered [108].

Two independent laboratories have reported that tubuloglomerular feedback responses are completely absent in adenosine A\(_{1A}\) receptor knockout mice and this is associated with impaired autoregulation of RBF and GFR especially in response to reductions in renal perfusion pressure [109–111]. Similarly, tubuloglomerular feedback responses are impaired in mice with deletion of the NTPDase1 gene, an extracellular ATPase that dephosphorylates ATP to ADP or ADP to AMP by deletion of ecto-5’-nucleotidase cd73 [99, 102]. Adenosine has a direct effect to constrict isolated perfused afferent arterioles and this effect is blocked by an adenosine A\(_{1A}\) receptor antagonist and in vessels obtained from A\(_{1A}\) knockout mice [104, 112]. As presented in (Fig. 3), previous studies have indicated that the vasoconstrictor response to adenosine in the afferent arteriole is mediated by G\(_{i}\)-dependent activa-
tigation of PLC via the subunit [113, 114] followed by release of DAG and IP3, the release of Ca2+ from intracellular stores, activation of PKC, depolarization of the membrane and Ca2+ influx in a manner analogous to the activation of the myogenic response by stretch or the vasoconstrictor response to angiotensin II via the angiotensin II receptor type I (AT1R) and Gq dependent pathways. Similarly, there is evidence that ATP, and possibly adenosine as well, stimulate the formation of 20-HETE in the afferent arteriole [115] and that 20-HETE may contribute to the vasoconstrictor response to these agonists by inhibiting BK channels and enhancing calcium influx [70]. In this regard, inhibitors of the formation of 20-HETE have been reported to impair autoregulation of tubuloglomerular feedback responses in the rat in vivo [116].

**INTERACTIONS BETWEEN G-PROTEIN COUPLED VASOCONSTRICTORS, MYOGENIC RESPONSE AND TUBULOGLOMERULAR FEEDBACK MECHANISMS IN THE AUTOREGULATION OF RBF AND GLOMERULAR CAPILLARY PRESSURE**

An examination of the pathways summarized in (Figs. 2 and 3) illustrates that elevations in transmural pressure (Fig. 2) and tubuloglomerular feedback (Fig. 3) activate the same second messenger signal transduction cascade characterized by activation of PLC, increases in DAG and IP3, cellular depolarization and influx of intracellular calcium. Moreover, this same pathway is involved in the response of the afferent arteriole to vasoconstrictor agonists acting via the AT1, P2X and endothelin ETA receptors [1, 117-119]. Given the convergence of these second messenger pathways, it is not sur-
prising that the myogenic response, tubuloglomerular feedback and G protein coupled vasoconstrictor pathways interact synergistically to regulate the tone of the afferent arteriole. For example, Inoue et al. [81] recently demonstrated that membrane stress/pressure induced responses were synergistically augmented in A7r5 cells and mesenteric arteries that normally respond poorly to membrane stress/stretch after low level Gq-receptor activation. They further demonstrated that the synergism was linked to increased production of 20-HETE. Other studies have indicated that activation of the angiotensin II AT1 or adenosine A1 receptor augments the myogenic response [104, 110, 114, 120, 121]. Similarly, blockade of the renin angiotensin system with angiotensin converting enzyme (ACE) inhibitors or AT1 receptor blockers (ARBs) attenuate tubuloglomerular feedback responses and shift the relationships between flow to the macula densa and stop flow pressure, and index of glomerular capillary pressure to the right [122, 123]. Although there is little direct data to support this hypothesis, one would also expect that increases in arterial pressure and myogenic tone would increase tubuloglomerular feedback responsiveness. Moreover, elevations in perfusion pressure should potentiate the dose response relationship to vasoconstrictor agonists, and subpressor levels of angiotensin, adenosine and endothelin should potentiate myogenic and tubuloglomerular feedback responsiveness. These types of interactions have been postulated to play a role in the enhanced myogenic responsiveness and elevated renal vascular resistance seen in angiotensin II models of hypertension and in the SHR, in which the kidney is generally protected from the development of glomerular injury until late in the disease process when arterial pressure rises beyond the reset autoregulatory range.

MODULATORS OF MYOGENIC RESPONSE AND TUBULOSCLEROSIS IN THE PATHOGENESIS OF GLOMERULAR SCLEROSIS AND CHRONIC KIDNEY DISEASE

Although the range of autoregulation may be shifted toward higher pressures, autoregulatory mechanisms are intact in most patients with essential hypertension and they do not develop proteinuria or significant renal injury [141, 142]. Similar renoprotection is seen in the SHR model of hypertension [15] in which the myogenic response of the preglomerular vasculature is enhanced [14, 143] perhaps due to elevated production of 20-HETE [73]. Recent studies have indicated that renal vascular resistance is also markedly elevated in the angiotensin II infused mouse model of hypertension which develops ischemic renal injury to the glomerulus rather than proteinuria, mesangial matrix expansion and focal glomerular sclerosis [144].

In contrast, renal autoregulation is impaired in patients with diabetes, other forms of proteinuric chronic kidney disease (CKD) and in African Americans with low renin forms of hypertension. These patients exhibit increased susceptibility to the development of progressive glomerulosclerosis in response to even modest elevations in pressure [9]. Indeed, this is the reason for the recommendation for strict control of blood pressure in patients with diabetes and CKD and it underlies the rationale for the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) that lower systemic pressure and reduce glomerular capillary pressure.
The increased susceptibility to renal injury observed in patients with diabetes and chronic kidney disease, as well as work done in wide variety of animal models of hypertension and diabetes, suggest that impairments in renal autoregulatory mechanisms leading to elevation in glomerular capillary pressure trigger the development of proteinuria and glomerulosclerosis. Work done in the 5/6 nephrectomy model of chronic kidney disease indicates that the remaining glomeruli hypertrophy and autoregulatory mechanisms are impaired. These animals exhibit hyperfiltration and elevated glomerular capillary pressure [9, 31, 145, 146]. With time these animals develop progressive proteinuria and glomerular sclerosis. Further support for a key role of alterations in renal hemodynamics in the development of renal injury are the findings that administration of calcium channel blockers, that further impair renal autoregulation, markedly accelerate the progression of renal disease in the 5/6 remnant kidney model [147-149].

Increased susceptibility to the development of proteinuria and focal segmental glomerulosclerosis has been observed in other rat models of hypertension that exhibit impaired autoregulation of RBF. These include the DOCA salt model of hypertension [29, 150] the unclipped kidney of 2 kidney 1 clip Goldblatt hypertensive rats [151, 152] and in the FHH rat [35, 153]. The FHH rat in particular develops proteinuria and focal segmental glomerulosclerosis at a relative young age that progresses to end stage renal disease. These rats have little or no myogenic response in preglomerular renal arteries but tubuloglomerular feedback responses are intact [28, 35, 154, 155]. Autoregulation of RBF is markedly impaired in these rats and glomerular capillary pressure increases following elevations in renal perfusion pressure [25, 34, 35]. Similarly, Dahl S rats and Brown Norway rats exhibit impaired dynamic autoregulation of RBF related to a defect in the myogenic control of the renal vasculature [26, 156]. Both of these strains rapidly develop proteinuria and progressive glomerular disease following the development of hypertension [32, 157-159]. Glomerular capillary pressure is also thought to be elevated in African Americans [36, 160] with salt-sensitive forms of hypertension and this is thought to underlie the increased susceptibility to the development of proteinuria and chronic kidney disease.

The mechanisms by which impaired autoregulation of RBF in diabetes, salt-sensitive forms of hypertension and chronic kidney disease promote the development of renal disease remain to be determined. A proposed mechanism is presented in (Fig. 4). The available data suggest that impaired autoregulation of RBF leads to an elevation in glomerular capillary pressure, which increases glomerular expression of transforming growth factor beta (TGF-β) through increases in stretch of the glomerular capillaries and adherent mesangial cells and podocytes [161-164] TGF-β is known to increase the production of collagen and fibronectin in cultured mesangial cells and podocytes [165]. There is also an increase in the renal expression of matrix metalloproteinase 2 (MMP2) which has been shown to increase the release of bound forms of TGF-β [166-168], activate the epidermal growth factor pathway and promote epithelial to mesenchymal transformation [169] which is critical to the development of renal fibrosis [170]. TGF-β has been shown to directly increase the permeability of isolated glomeruli to albumin [171, 172]. Damage to the glomerular filtration barrier and increased filtration of macromolecules and/or growth factors may trigger a positive feedback loop that further stimulates podocytes, mesangial cells and renal tubular epithelial cells to upregulate the expression of TGF-β, increasing the production of extracellular matrix. This may be one of the pathways for the development of focal glomerulosclerosis, renal interstitial fibrosis and tubular necrosis in hypertensive and diabetic patients. Ultimately, the sustained overexpression of TGF-β stimulates the production of extracellular matrix and leads to the collapse of glomerular capillaries (glomerulosclerosis), renal interstitial fibrosis, loss of nephrons and chronic renal failure.

The mechanism by which TGF-β increases the glomerular permeability to albumin is still unknown. We have reported that TGF-β inhibits the synthesis of 20-HETE in isolated glomeruli and that pretreatment of glomeruli with 20-HETE mimetics opposes the effects of TGF-β to increase the glomerular permeability of albumin [173]. Moreover, inhibitors of the synthesis of 20-HETE mimic the action of TGF-β to increase the albumin permeability of the glomerulus and development of proteinuria [174]. These findings suggest that 20-HETE may also play a role in maintaining glomerular barrier function and that TGF-β may initiate the development of proteinuria and renal disease in part by inhibiting the formation of 20-HETE.

There is also overwhelming evidence that over expression of TGF-β plays a key role in the pathogenesis of renal fibrosis associated with exposure to nephrotoxins, renal ischemia and immune injury, as well as hypertension and diabetic nephropathy. Increased circulating and/or renal concentrations of TGF-β mRNA or protein have been reported in patients with diabetic nephropathy [175-178], following transplant rejection [179] and cyclosporine-induced nephropathy [180] and in various forms of glomerulosclerosis [181, 182]. Increases in renal expression of TGF-β have been reported in every animal model of renal injury examined to date [165]. This includes use of anti-thymocyte or anti-glomerular basement membrane serum and Heyman nephritis [183], cyclosporine and puromycin nephropathies [184, 185], remnant kidney [186, 187], ureteral obstruction [188], chronic allograft rejection [180] and radiation injury [189], as well as animal models of diabetes-induced renal injury including streptozotocin induced rodent models [178, 190], the biobreeding (BB) rat and the non obese diabetic (NOD) mouse model [191]. Hypertension models linked to elevated levels of TGF-β include: L-NAME [192, 193] and angiotensin II treated animals [165, 194], deoxycorticosterone acetate-salt hypertensive rats [150] and genetic models including stroke prone SHR rats [195] and Dahl S rats [172, 196]. Previous studies have shown that treatment of rats and mice with TGF-β2 induces a renal interstitial fibrosis in the outer medulla resembling that seen in patients with hypertension [197, 198]. Transgenic mice that over express TGF-β also develop glomerular lesions and tubulointerstitial renal disease resembling that seen in patients with hypertension and diabetes [199-203].

The most direct evidence for a role for TGF-β in the pathogenesis of renal disease comes from inhibitor studies. These studies have shown that chronic treatment of rats with
a TGF-β neutralizing antibody [204], decorin, an endogenous inhibitor of TGF-β [205], or antisense constructs that downregulate the expression of TGF-β or TβRII [193] reduce the degree of glomerulosclerosis in the anti-Thy1 model of glomerulonephritis. Several investigators have reported that knock-down of the production of TGF-β with antisense TGF-β1 oligodeoxynucleotides or by blocking the actions of the TGF-β with a neutralizing antibody also reduces the degree of proteinuria and glomerular damage in diabetic mice [190, 206-208]. Beneficial effects of TGF-β neutralizing antibodies have also been reported in rats with puromycin nephropathy [185] and in mice with cyclosporin-induced nephropathy [209]. These studies indicate that TGF-β levels are elevated in diabetes, hypertension and following renal injury. They also suggest that TGF-β plays a causal role in the pathogenesis of renal fibrosis associated with these conditions. Sustained overproduction of TGF-β [196] also leads to apoptosis of podocytes [210, 211], mesangial cells [212] and tubular epithelial cells [213, 214], damage to the glomerular filtration barrier, proliferation of mesangial cells, increased deposition of extracellular matrix, and collapse of glomerular capillaries. TGF-β also promotes epithelial-mesenchymal transformation, [169, 170, 215, 216] leading to renal interstitial fibrosis, loss of capillaries and tubular necrosis.

**POTENTIAL FOR NEW THERAPEUTIC STRATEGIES FOR IMPROVED RENAL PROTECTION**

Overall, there is strong evidence that impaired autoregulation of RBF leading to increased transmission of fluctuations in system pressure to the glomerulus and increased glomerular capillary pressure (Pgc). Elevated Pgc results in increased expression of matrix metalloproteases and transforming growth factor beta (TGF-β). Increased TGF-β promotes glomerulosclerosis, increased glomerular permeability to albumin (Palb), myoepithelial transformation, proteinuria and renal interstitial fibrosis.
sion, cardiac arrhythmias and vasospasm. These same pathways also play a key role in cell growth and proliferation so these drugs may promote the development of vascular hypertrophy and arteriosclerosis or certain forms of cancer. As a result, it appears that the most effective strategy to slow the progression of renal disease for the foreseeable future will remain strict control of diabetes and the associated renal vasodilation and to reduce systemic pressure with ACE inhibitors and ARBs which lower glomerular capillary pressure by dilating the efferent arteriole. This approach may someday be augmented with the emergence of new antifibrotic agents that block the actions of TGF-β and matrix metalloproteinase 2. Indeed, recent data have been very promising in experimental animal models of diabetes, hypertension and renal disease. However, none of these compounds have yet entered clinical development for the prevention of hypertension and/or diabetic nephropathy in humans.

CONFLICT OF INTEREST

The authors of this article have no conflict of interest.

ACKNOWLEDGEMENTS

All authors were involved in writing and editing of this article.

LIST OF ABBREVIATIONS

ACE = Angiotensin converting enzyme
ARB = Angiotensin receptor blocker
BK = Large conductance potassium channel
DAG = Diacylglycerol
DOCA = Deoxycorticosterone acetate
EET = Eicosatetraenoic acid
ENaC = Epithelial sodium channels
FHH rats = Fawn hooded hypertensive
GFR = Glomerular filtration rate
IP3 = Inositol trisphosphate
NOS = Nitric oxide synthase
MMP2 = Matrix metalloproteinase 2
P Alb = Glomerular permeability to albumin
PLC = Phospholipase C
PKC = Protein kinase C
RBF = Renal blood flow
SHR = Spontaneously hypertensive rats
TGF-β = Transforming growth factor beta
TRPC6 = Transient receptor potential canonical 6
TRPM4 = Transient receptor potential melastatin 4

VGCC = Voltage gated calcium channel
VSM = Vascular smooth muscle
20-HETE = 20-hydroxyeicosatetraenoic acid

REFERENCES

[1] Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 1996; 76: 425-536.
[2] Schrenneman J, Briggs JP. Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice. Kidney Int 2008; 74: 418-26.
[3] Pires SL, Barnes C, Sassard J, Julien C. Renal blood flow dynamics and arterial pressure lability in the conscious rat. Hypertension 2011; 36: 147-52.
[4] Chon KH, Chen YM, Holstein-Rathlou NH, Marsh DJ, Marmarell VZ. On the efficacy of linear system analysis of renal autoregulation in rats. IEEE Trans Biomed Eng 1993; 40: 8-20.
[5] Abu-Amarah I, Bidani AK, Hacioglu R, Williamson GA, Griffin KA. Differential effects of salt on renal hemodynamics and potential pressure transmission in stroke-prone and stroke-resistant spontaneously hypertensive rats. Am J Physiol Renal Physiol 2005; 289: F305-13.
[6] Holstein-Rathlou NH, Wagner AJ, Marsh DJ. Tubuloglomerular feedback dynamics and renal blood flow autoregulation in rats. Am J Physiol 1991; 260: F53-68.
[7] Daniels FH, Arendshorst WJ. Tubuloglomerular feedback kinetics in spontaneously hypertensive and Wistar-Kyoto rats. Am J Physiol 1990; 259: F529-34.
[8] Cupples WA, Novak P, Novak V, Salevsky FC. Spontaneous blood pressure fluctuations and renal blood flow dynamics. Am J Physiol 1996; 270: F82-9.
[9] Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhiser R. Protective importance of the myogenic response in the renal circulation. Hypertension 2009; 54: 393-8.
[10] Loutzenhiser R, Griffin KA, Bidani AK. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens 2006; 15: 41-9.
[11] Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ Res 2002; 90: 1316-24.
[12] Loutzenhiser R, Bidani AK, Wang X. Systolic pressure and the myogenic response of the renal afferent arteriole. Acta Physiol Scand 2004; 181: 407-13.
[13] Loutzenhiser R, Griffin K, Williamson G, Bidani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006; 296: R1153-67.
[14] Arendshorst WJ, Beierwaltes WH. Renal and nephron hemodynamics in spontaneously hypertensive rats. Am J Physiol 1979; 236: F246-51.
[15] Griffin KA, Churchill PC, Picken M, Webb RC, Kurtz TW, Bidani AK. Differential salt-sensitivity in the pathogenesis of renal damage in SHR and stroke prone SHR. Am J Hypertens 2001; 14: 311-20.
[16] Iversen BM, Sekse I, Ofstad J. Resetting of renal blood flow autoregulation in spontaneously hypertensive rats. Am J Physiol 1987; 252: F480-8.
[17] Roman RJ, Cowley AW, Jr. Abnormal pressure-diuresis-natriuresis response in spontaneously hypertensive rats. Am J Physiol 1985; 248: F199-205.
[18] Folkow B. Myogenic mechanisms in the control of systemic resistance. Introduction and historical background. J Hypertens Suppl 1989; 7: S1-4.
[19] Hayashi K, Epstein M, Loutzenhiser R. Enhanced myogenic responsiveness of renal interlobular arteries in spontaneously hypertensive rats. Hypertension 1992; 19: 153-60.
[20] Ren Y, D’Ambrosio MA, Liu R, Pagano PJ, Garvin JL, Carretero OA. Enhanced myogenic response in the afferent arteriole of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010; 298: H1769-75.
[21] Gebremedhin D, Ma YH, Imig JD, Harder DR, Roman RJ. Role of cytochrome P-450 in elevating renal vascular tone in spontaneously hypertensive rats. J Vasc Res 1993; 30: 53-60.
Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal van Dokkum RP, Alonso-Galicia M, Provoost AP, Jacob HJ, Roman RJ. Harder DR. Pressure-dependent membrane depolarization in cat Folkow B. A study of the factors influencing the tone of denervated Folkow B. Impaired renal autoregulation: implications for the Braden BF. Vascular smooth muscle alpha v beta 3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res 1996; 79: 821-6. Martinez-Lemus LA, Crow T, Davis MJ, Meineger GA, alphavbeta3- and alphabeta1-integrin blockade inhibits myogenic constriction of skeletal muscle resistance arterioles. Am J Physiol Heart Circ Physiol 2005; 289: H322-9. Jermin NL, Drummond HA. Myogenic vasoconstriction in mouse renal interlobar arteries: role of endogenous beta and gammaENaC. Am J Physiol Renal Physiol 2006; 29: F1184-91. Jermin NL, Drummond HA. Vascular ENaC proteins are required for renal myogenic constriction. Am J Physiol Renal Physiol 2005; 289: F891-901. Drummond HA, Gebremedhin D, Harder DR. Dегenerin/epithelial Nav channel proteins: components of a vascular mechanosensor. Hypertension 2004; 44: 643-8. VanLandingham LG, Gannon KP, Drummond HA. Pressure-induced constriction is inhibited in a mouse model of reduced betaENaC. Am J Physiol Regul Integr Physiol 2009; 297: R723-8. Wu X, Meineger MJ. Characterization of stretch-activated cation current in coronary smooth muscle cells. Am J Physiol Heart Circ Physiol 2001; 280: H1751-61. Davis MJ, Meineger GA, Zwieja DC. Stretch-induced increases in intracellular calcium of isolated vascular smooth muscle cells. Am J Physiol 1992; 263: H1292-9. Davis MJ, Donovitz JA, Hood JD. Stretch-activated single-channel and whole cell currents in vascular smooth muscle cells. Am J Physiol 1992; 262: C1083-9. Mederos y Schnitzler M, Storch U, Meibers S, Mederos y Schnitzler M, Storch U, Meibers S, Muller R, Meiners J. Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury. Am J Physiol Renal Physiol 2001; 300: F330-8. Mederos y Schnitzler M, Storch U, Meibers S, Muller R, Meiners J. Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury. Am J Physiol Renal Physiol 2001; 300: F330-8. Mederos y Schnitzler M, Storch U, Meibers S, Muller R, Meiners J. Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury. Am J Physiol Renal Physiol 2001; 300: F330-8.
Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback. Am J Physiol 1993; 264:F395-404.

Ito O, Alonso-Galicia M, Hopp KA, Roman RJ. Localization of cytochrome P-450 4A1 isoforms along the rat nephron. Am J Physiol 1998; 274:F395-404.

Osswald H, Nabakowski G, Hermes HH. Role of adenosine in the regulation of rat renal Na+,K+-ATPase. J Clin Invest 1997; 99:1224-30.

Muthalif MM, Benter IF, Karzoun N, Ma YH, Gebremedhin D, Schwartzman ML, Benter IF, Karzoun N, Maliki KU. Small GTP binding protein Ras contributes to non-neurinephrine-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Prog Clin Biol Res 1993; 372:126-36.

Nowicki S, Chen SL, Aizman O, et al. 20-Hydroxyeicosatetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+,K+-ATPase. J Clin Invest 1997; 99:1224-30.

Muthalif MM, Benter IF, Karzoun N, Maliki KU. Small GTP binding protein Ras contributes to non-neurinephrine-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Prog Clin Biol Res 1993; 372:126-36.

Toro L, Alioua A, Mahajan A, Kaldunski M, Ortiz de Montellano PR, Sui Z, Roman RJ. Inhibition of renal vascular 20-HETE production elevations in pressure. Am J Physiol 1994; 266:H1879-85.

Thomson S, Bao D, Deng A, Vallon V. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. J Clin Invest 2000; 106:289-98.

Kishore BK, Isaac J, Fausther M, et al. Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol 2005; 288:F132-43.

Osswald H, Hermes HH, Nabakowski G. Role of adenosine in signal transmission of tubuloglomerular feedback. Kidney Int Suppl 1982; 12:S136-42.

Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006; 86:901–40. Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. J Clin Invest 2003; 112:1895-905.

Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Renal autoregulation in P2X1 knockout mice. Acta Physiol Scand 2004; 181:445-53.

Osmund DA, Inscho EW. P2X2(1) receptor blockade inhibits whole kidney autoregulation of renal blood flow in vivo. Am J Physiol Renal Physiol 2010; 298:F132-43.

Schnermann J. Maintained tubuloglomerular feedback responses during acute inhibition of P2 purinergic receptors in mice. Am J Physiol Renal Physiol 2011; 300:F339-44.

Sun D, Samuelson LC, Yang T, et al. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 2001; 98:9983-8.

Hashimoto S, Huang Y, Briggs J, Schnermann J. Reduced autoregulatory effectiveness in adenosine 1 receptor-deficient mice. Am J Physiol Renal Physiol 2006; 290:F888-91.

Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol 2003; 65:501-29.

Williams JM, Sarkis A, Lopez B, Ryan RP, Flasch AK, Roman RJ. Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension 2007; 49:687-94.

Roman RJ, Cowley AW, Jr., Garcia-Estan J, Lombard JH. Pressure diuresis in volume-expanded rats. Cortical and medullary hemodynamics. Hypertension 1988; 12:168-76.

Ito S. Characteristics of isolated perfused juxtaglomerular apparatus. Kidney Int Suppl 1998; 67:S46-8.
mouse afferent arterioles to adenosine. Acta Physiol 2007; 19: 89-97.

[115] Zhao X, Inscho EW, Bondiola M, Falck JR, Imig JD. The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasconstriction. Am J Physiol Heart Circ Physiol 2001; 282: F927-44.

[116] Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, Roman RJ. Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol 1994; 266: F934-41.

[117] Inscho EW. P2 receptors in regulation of renal microvascular function. Am J Physiol Renal Physiol 2001; 280: F927-44.

[118] Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011; 91: 1-77.

[119] Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112: 417-28.

[120] Lai EY, Patzak A, Steege A, et al. Contribution of adenosine receptors in the control of arterial tone and adenosine-angiotensin II interaction. Kidney Int 2006; 70: 690-8.

[121] Weihprecht H, Lorenz NJ, Briggs JP, Schnerrmann J. Synergistic effects of angiotensin II and adenosine in the renal microvasculature. Am J Physiol 1994; 266:F227-39.

[122] Traynor T, Yang T, Huang YG, et al. Tubuloglomerular feedback in ACE-deficient mice. Am J Physiol 1999; 276: F751-7.

[123] Schnerrmann JB, Traynor T, Yang T, et al. Absence of tubuloglomerular feedback responses in AT1 receptor-deficient mice. Am J Physiol 1997; 273: F315-20.

[124] Bluntz RC, Deng A, Lottie M, et al. The complex role of nitric oxide in the regulation of glomerular ultrafiltration. Kidney Int 2002; 6: 782-5.

[125] Morsing P, Persson AE. Effect of prostaglandin synthesis inhibition on the tubuloglomerular feedback control in the rat kidney. Ren Physiol Biochem 1992; 15: 66-72.

[126] Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.

[127] Cohen RA, Vanhouptide PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337-49.

[128] Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol 1998; 275: F370-8.

[129] Taniguchi J, Furukawa KI, Shigekawa M. Maxi K+ channels are a critical modulator of subsequent hypertension and glomerular injury in the rat remnant kidney model. Hypertension 2002; 39: 111-5.

[130] Morsing P, Persson AE. Effect of prostaglandin synthesis inhibition on the tubuloglomerular feedback control in the rat kidney. Ren Physiol Biochem 1992; 15: 66-72.

[131] Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.

[132] Lai EY, Patzak A, Steege A, et al. Contribution of adenosine receptors in the control of arterial tone and adenosine-angiotensin II interaction. Kidney Int 2006; 70: 690-8.

[133] Weihprecht H, Lorenz NJ, Briggs JP, Schnerrmann J. Synergistic effects of angiotensin II and adenosine in the renal microvasculature. Am J Physiol 1994; 266:F227-39.

[134] Traynor T, Yang T, Huang YG, et al. Tubuloglomerular feedback in ACE-deficient mice. Am J Physiol 1999; 276: F751-7.

[135] Schnerrmann JB, Traynor T, Yang T, et al. Absence of tubuloglomerular feedback responses in AT1 receptor-deficient mice. Am J Physiol 1997; 273: F315-20.

[136] Bluntz RC, Deng A, Lottie M, et al. The complex role of nitric oxide in the regulation of glomerular ultrafiltration. Kidney Int 2002; 6: 782-5.

[137] Morsing P, Persson AE. Effect of prostaglandin synthesis inhibition on the tubuloglomerular feedback control in the rat kidney. Ren Physiol Biochem 1992; 15: 66-72.

[138] Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.

[139] Cohen RA, Vanhouptide PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337-49.

[140] Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol 1998; 275: F370-8.

[141] Taniguchi J, Furukawa KI, Shigekawa M. Maxi K+ channels are a critical modulator of subsequent hypertension and glomerular injury in the rat remnant kidney model. Hypertension 2002; 39: 111-5.

[142] Morsing P, Persson AE. Effect of prostaglandin synthesis inhibition on the tubuloglomerular feedback control in the rat kidney. Ren Physiol Biochem 1992; 15: 66-72.

[143] Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.

[144] Cohen RA, Vanhouptide PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337-49.

[145] Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol 1998; 275: F370-8.

[146] Taniguchi J, Furukawa KI, Shigekawa M. Maxi K+ channels are a critical modulator of subsequent hypertension and glomerular injury in the rat remnant kidney model. Hypertension 2002; 39: 111-5.

[147] Morsing P, Persson AE. Effect of prostaglandin synthesis inhibition on the tubuloglomerular feedback control in the rat kidney. Ren Physiol Biochem 1992; 15: 66-72.

[148] Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.

[149] Cohen RA, Vanhouptide PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337-49.

[150] Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol 1998; 275: F370-8.

[151] Taniguchi J, Furukawa KI, Shigekawa M. Maxi K+ channels are a critical modulator of subsequent hypertension and glomerular injury in the rat remnant kidney model. Hypertension 2002; 39: 111-5.

[152] Morsing P, Persson AE. Effect of prostaglandin synthesis inhibition on the tubuloglomerular feedback control in the rat kidney. Ren Physiol Biochem 1992; 15: 66-72.

[153] Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.

[154] Cohen RA, Vanhouptide PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337-49.

[155] Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol 1998; 275: F370-8.

[156] Taniguchi J, Furukawa KI, Shigekawa M. Maxi K+ channels are a critical modulator of subsequent hypertension and glomerular injury in the rat remnant kidney model. Hypertension 2002; 39: 111-5.

[157] Morsing P, Persson AE. Effect of prostaglandin synthesis inhibition on the tubuloglomerular feedback control in the rat kidney. Ren Physiol Biochem 1992; 15: 66-72.

[158] Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.

[159] Cohen RA, Vanhouptide PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337-49.
Shankland SJ, Pippin J, Pichler RH, et al. Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 1996; 50: 116-24.

[184] Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1992; 141: 1381-90.

[185] Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 2004; 65: 106-15.

[186] Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerulosclerosis in the rat remnant kidney. J Clin Invest 1995; 96: 953-60.

[187] Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: the role of the renin-angiotensin system. Kidney Int 1997; 5: 1553-67.

[188] Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44: 313-21.

[189] Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-72.

[190] Benigni A, Zonca C, Corna D, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-24.

[191] Sharma K, Ziyadeh FN. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994; 267: F1094-01.

[192] Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14: 1132-44.

[193] Kashiwagi M, Shinozaki M, Hirakata H, et al. Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000; 11: 616-24.

[194] Mori T, Cowley AW, Jr. Role of pressure in angiotensin II-induced renal injury: chronic servo-control of renal perfusion pressure in rats. Hypertension 2004; 43: 752-9.

[195] Hamaguchi A, Kim S, Ohta K, et al. Transforming growth factor-beta 1 expression and phenotypic modulation in the kidney of hypertensive rats. Hypertension 1995; 26: 199-207.

[196] Tamaki K, Okuda S, Nakayama T, Fujishima M. Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 1996; 7: 2578-89.

[197] Kelly FJ, Anderson S, Thompson MM, et al. Acute and chronic renal effects of recombinant human TGF-beta2 in the rat. J Am Soc Nephrol 1999; 10: 1964-73.

[198] Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 2000; 58: 2367-76.

[199] Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipo dystrophy-like syndrome in PEPC-K-TGF-beta1 transgenic mice. J Clin Invest 1997; 100: 2697-713.

[200] Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74: 991-1003.

[201] Krag S, Osterby R, Chai Q, Nielsen CB, Hermans C, Wogensen L. Transforming growth factor-beta 1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man. Lab Invest 2000; 80: 1855-68.

[202] Mozes MM, Bottleper EP, Jacot TA, Kopp JB. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J Am Soc Nephrol 1999; 10: 271-80.

[203] Wogensen L, Nielsen CB, Hjorth P, et al. Under control of the TGF-beta promoter, transfected growth factor-beta1 induces accumulation of glomerular extracellular matrix in transgenic mice. Diabetes 1999; 48: 182-92.

[204] Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antisense against transforming growth factor beta 1. Nature 1990; 346: 371-374.
[205] Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360: 361-4.
[206] Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003; 300: 16-22.
[207] Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000; 278: F628-34.
[208] Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000 5; 97: 8015-20.
[209] Ling H, Li X, Jha S, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003; 14: 377-88.
[210] Ding G, Reddy K, Kapasi AA, et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283: F173-80.
[211] Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-16.
[212] Lodha S, Dani D, Mehta R, et al. Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med 2002; 8: 830-40.
[213] Dai C, Yang J, Liu Y. Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 2003; 278: 12537-45.
[214] Bhaskaran M, Reddy K, Radhakrishanan N, Franki N, Ding G, Singhal PC. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 2003; 284: F955-65.
[215] Wang SN, LaPage J, Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 2000; 57: 1002-14.
[216] Yard BA, Chorianopoulos E, Herr D, van der Woude FJ. Regulation of endothelin-1 and transforming growth factor-beta1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 2001; 16: 1769-75.